Cited by 2,217CAR-T cell therapy researchImmune Cell Function and InteractionImmunotherapy and Immune Responses

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Open access

Liu, Enli, Marin, David, Banerjee, Pinaki, Macapinlac, Homer A., Thompson, Philip, Basar, Rafet, Nassif Kerbauy, Lucila, Overman, Bethany, Thall, Peter, Kaplan, Mecit, Nandivada, Vandana, Kaur, Indresh, Nunez Cortes, Ana, Cao, Kai, Daher, May, Hosing, Chitra, Cohen, Evan N., Kebriaei, Partow, Mehta, Rohtesh, Neelapu, Sattva, Nieto, Yago, Wang, Michael, Wierda, William, Keating, Michael, Champlin, Richard, Shpall, Elizabeth J., Rezvani, Katayoun·2020·New England Journal of Medicine

DOI 10.1056/nejmoa1910607PMC PMC7101242

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations. METHODS: CAR-NK cells per kilogram of body weight) after lymphodepleting chemotherapy. RESULTS: The administration of CAR-NK cells was not associated with the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease, and there was no increase in the levels of inflammatory cytokines, including interleukin-6, over baseline. The maximum tolerated dose was not reached. Of the 11 patients who were treated, 8 (73%) had a response; of these patients, 7 (4 with lymphoma and 3 with CLL) had a complete remission, and 1 had remission of the Richter's transformation component but had persistent CLL. Responses were rapid and seen within 30 days after infusion at all dose levels. The infused CAR-NK cells expanded and persisted at low levels for at least 12 months. CONCLUSIONS: Among 11 patients with relapsed or refractory CD19-positive cancers, a majority had a response to treatment with CAR-NK cells without the development of major toxic effects. (Funded by the M.D. Anderson Cancer Center CLL and Lymphoma Moonshot and the National Institutes of Health; ClinicalTrials.gov number, NCT03056339.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1910607

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citation
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citation
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer
Miller, J. S., Soignier, Y., Panoskaltsis‐Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D. H., Le, C. T., DeFor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,894

Flagged first, then by citations

Show all 37 references

Sorted by citations

Items 201–300 of 1,000

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells
Bexte, T., Albinger, N., Al-Ajami, A., Wendel, P., Buchinger, L., Geßner, A., Alzubi, J., Särchen, V., Vogler, M., Rasheed, H. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52388-1 · Cited by 97
In Vivo Tracking of Cell Viability for Adoptive Natural Killer Cell‐Based Immunotherapy by Ratiometric NIR‐II Fluorescence Imaging
Liao, N., Su, L., Zheng, Y., Zhao, B., Wu, M., Zhang, D., Yang, H., Liu, X., & Song, J. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106730 · Cited by 94
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
Sheffer, M., Lowry, E., Beelen, N. A., Borah, M., Amara, S. N.-A., Mader, C. C., Roth, J. A., Tsherniak, A., Freeman, S. S., Dashevsky, O., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00889-w · Cited by 96
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells
Du, Z., Ng, Y., Zha, S., & Wang, S. (2021) · Molecular Therapy: Methods & Clinical Development · doi:10.1016/j.omtm.2021.10.014 · Cited by 79
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 96
CAR T cells for treating autoimmune diseases
Blache, U., Tretbar, S., Koehl, U., Mougiakakos, D., & Fricke, S. (2023) · RMD Open · doi:10.1136/rmdopen-2022-002907 · Cited by 98
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
Diorio, C. J., Teachey, D. T., & Grupp, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00959-y · Cited by 95
Advancing cell-based cancer immunotherapy through stem cell engineering
Li, Y.-R., Dunn, Z. S., Yu, Y., Li, M., Wang, P., & Yang, L. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.02.009 · Cited by 95
Chemokine networks modulating natural killer cell trafficking to solid tumors
Yao, X., & Matosevic, S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.12.003 · Cited by 96
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
Swan, D., Madduri, D., & Hocking, J. S. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01191-8 · Cited by 110
A robust platform for expansion and genome editing of primary human natural killer cells
Huang, R., Lai, M., Shih, H.-A., & Lin, S. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201529 · Cited by 86
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
Elahi, R., Heydari, A. H., Hadiloo, K., & Esmaeilzadeh, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10246-3 · Cited by 95
Interleukin 15 in Cell-Based Cancer Immunotherapy
Zhou, Y., Husman, T., Cen, X., Tsao, T., Brown, J., Bajpai, A., Li, M., Zhou, K., & Yang, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137311 · Cited by 92
Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy
Li, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 94
CAR-NK cell therapy: promise and challenges in solid tumors
Balkhi, S., Zuccolotto, G., Spirito, A. D., Rosato, A., & Mortara, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1574742 · Cited by 101
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Roselli, E., Faramand, R. G., & Davila, M. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142030 · Cited by 90
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
Li, H., Song, W., Li, Z., & Zhang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992232 · Cited by 95
CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond
Lu, J., Ma, Y., Li, Q., Xu, Y., Xue, Y., & Xu, S. (2024) · Biomarker Research · doi:10.1186/s40364-024-00637-2 · Cited by 95
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Ghemrawi, R., Abuamer, L., Kremesh, S., Hussien, G., Ahmed, R., Mousa, W. K., Khoder, G., & Khair, M. (2024) · Biomedicines · doi:10.3390/biomedicines12092158 · Cited by 97
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
The role of natural killer cell in gastrointestinal cancer: killer or helper
Wang, F., Lau, J. K. C., & Yu, J. Q. (2020) · Oncogene · doi:10.1038/s41388-020-01561-z · Cited by 90
Immune Therapy Resistance and Immune Escape of Tumors
Seliger, B., & Massa, C. (2021) · Cancers · doi:10.3390/cancers13030551 · Cited by 84
Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy
Xue, D., Lu, S., Zhang, H., Li, Z., Dai, Z., Kaufman, D. S., & Zhang, J. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.02.003 · Cited by 86
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 91
Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma
Zhao, Q., Sun, X., Wu, B., Shang, Y., Huang, X., Dong, H., Liu, H., Chen, W., Gui, R., & Li, J. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00738-8 · Cited by 84
CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity
Kong, Y., Li, J., Zhao, X., Wu, Y., & Chen, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1519671 · Cited by 96
Materials for Improving Immune Cell Transfection
Kumar, A. R. K., Shou, Y., Chan, B., Krishaa, L., & Tay, A. K. P. (2021) · Advanced Materials · doi:10.1002/adma.202007421 · Cited by 83
Research progress of interleukin-15 in cancer immunotherapy
Cai, M., Huang, X., Huang, X., Ju, D., Zhu, Y. Z., & Li, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1184703 · Cited by 83
Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells
Yang, M., Zhang, S., Sun, L., Huang, L., Yu, J., Zhang, J.-H., Tian, Y., Han, C., & Ma, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02175-9 · Cited by 99
NK Cell Therapy: A Rising Star in Cancer Treatment
Du, N., Guo, F.-F., Wang, Y.-F., & Cui, J. (2021) · Cancers · doi:10.3390/cancers13164129 · Cited by 72
Recent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 86
IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity
Landoni, E., Woodcock, M. G., Barragán, G. A., Casirati, G., Cinella, V., Stucchi, S., Flick, L. M., Withers, T. A., Hudson, H., Casorati, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44310-y · Cited by 82
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells
Thangaraj, J. L., Coffey, M., Lopez, E., & Kaufman, D. S. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.06.009 · Cited by 92
Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins
Huang, R., Shih, H.-A., Lai, M., Chang, Y.-J., & Lin, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01008 · Cited by 81
Magneto-Activation and Magnetic Resonance Imaging of Natural Killer Cells Labeled with Magnetic Nanocomplexes for the Treatment of Solid Tumors
Sim, T., Choi, B., Kwon, S. W., Kim, K.-S., Choi, H., Ross, A. G., & Kim, D. (2021) · ACS Nano · doi:10.1021/acsnano.1c01889 · Cited by 82
Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
Pinto, S., Pahl, J. H. W., Schottelius, A. J. G., Carter, P. J., & Koch, J. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.09.007 · Cited by 81
Chronic lymphocytic leukemia treatment algorithm 2022
Hampel, P. J., & Parikh, S. A. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00756-9 · Cited by 90
CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary
Melero, I., Sanmamed, M. F., Glez‐Vaz, J., Luri‐Rey, C., Wang, J., & Chen, L. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1029 · Cited by 81
Generating natural killer cells for adoptive transfer: expanding horizons
Kundu, S., Gurney, M. E., & O'Dwyer, M. E. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2020.12.002 · Cited by 81
Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy
Zhang, C., Hu, Y., Xiao, W., & Tian, Z. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00732-6 · Cited by 80
IPSC-derived CAR-NK cells for cancer immunotherapy
Lin, X., Sun, Y., Dong, X., Liu, Z., Sugimura, R., & Xie, G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115123 · Cited by 88
The paths and challenges of “off-the-shelf” CAR-T cell therapy: an overview of clinical trials
Moradi, V., Omidkhoda, A., & Ahmadbeigi, N. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115888 · Cited by 80
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Lamb, M. G., Rangarajan, H. G., Tullius, B. P., & Lee, D. A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02277-x · Cited by 79
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Marofi, F., Saleh, M. M., Rahman, H. S., Suksatan, W., Al-Gazally, M. E., Abdelbasset, W. K., Thangavelu, L. P., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02462-y · Cited by 82
NK cell-based tumor immunotherapy
Zhang, H., Yang, L., Wang, T., & Li, Z. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.001 · Cited by 82
Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
Capuano, C., Pighi, C., Battella, S., Federicis, D. D., Galandrini, R., & Palmieri, G. (2021) · Cancers · doi:10.3390/cancers13102500 · Cited by 86
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
Merino, A. M., Maakaron, J. E., & Bachanová, V. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101073 · Cited by 76
Biological effects of IL-15 on immune cells and its potential for the treatment of cancer
Zhang, S., Zhao, J., Bai, X., Handley, M., & Shan, F. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107318 · Cited by 82
Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
Feng, J., Xu, H.-C., Cinquina, A., Wu, Z., Chen, Q., Zhang, P., Wang, X., Shan, H., Xu, L., Zhang, Q., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10092-9 · Cited by 77
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Dai, X., Guo, Y., Hu, Y., Bao, X., Zhu, X., Fu, Q., Zhang, H., Tong, Z., Liu, L., Zheng, Y., et al. (2021) · Theranostics · doi:10.7150/thno.54648 · Cited by 79
The future of affordable cancer immunotherapy
Schaft, N., Dörrie, J., Schuler, G., Schuler‐Thurner, B., Sallam, H., Klein, S., Eisenberg, G., Frankenburg, S., Lotem, M., & Khatib, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1248867 · Cited by 81
Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy
Wilk, A. J., Benner, N. L., Vergara, R., Haabeth, O. A. W., Levy, R., Waymouth, R. M., Wender, P. A., & Blish, C. A. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002355 · Cited by 78
Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles
Goldenson, B. H., Huang, Z., Wang, Y. M., Heragu, N., Bernareggi, D., Ruiz-Cisneros, A., Bahena, A., Ask, E. H., Hoel, H. J., Malmberg, K., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.561553 · Cited by 76
Current and future treatment strategies in chronic lymphocytic leukemia
Patel, K., & Pagel, J. M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01054-w · Cited by 81
Systematic Review of Available CAR-T Cell Trials around the World
Barros, L. R. C., Couto, S. C. F., Santurio, D. S., Paixão, E. A., Cardoso, F. C., da Silva, V. J., Klinger, P. H. D. S., Ribeiro, P. D. A. C., Rós, F. A., de Oliveira, T. G. M., et al. (2022) · Cancers · doi:10.3390/cancers14112667 · Cited by 79
Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
Mhaidly, R., & Verhoeyen, E. (2020) · Cancers · doi:10.3390/cancers12071915 · Cited by 76
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity
Bernard, P.-L., Delconte, R. B., Pastor, S., Laletin, V., Silva, C. C. D., Goubard, A., Josselin, E., Castellano, R., Krug, A., Vernerey, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004244 · Cited by 75
Antibody variable region engineering for improving cancer immunotherapy
Lou, H., & Cao, X. (2022) · 癌症：英文版 · doi:10.1002/cac2.12330 · Cited by 78
Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
Sánchez‐Martínez, D., Tirado, N., Mensurado, S., Martínez‐Moreno, A., Romecín, P. A., Gutiérrez‐Agüera, F., Correia, D. V., Silva‐Santos, B., & Menéndez, P. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005400 · Cited by 79
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Wang, X., Jasinski, D. L., Medina, J. L., Spencer, D. M., Foster, A. E., & Bayle, J. H. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001510 · Cited by 75
Umbilical Cord Blood Transplants: Current Status and Evolving Therapies
Gupta, A. O., & Wagner, J. E. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.570282 · Cited by 75
Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
Lee, D., Huntoon, K. M., Wang, Y., Jiang, W., & Kim, B. Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202007576 · Cited by 74
Cytokine-induced memory-like natural killer cells for cancer immunotherapy
Tarannum, M., & Romee, R. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02655-5 · Cited by 76
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells
Maddineni, S., Silberstein, J. L., & Sunwoo, J. B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004693 · Cited by 74
Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy
Dogan, M., Karhan, E., Kozhaya, L., Placek, L., Chen, X., Yiğit, M., & Unutmaz, D. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100856 · Cited by 78
Biomaterials for in situ cell therapy
Wang, C., Wang, S., Kang, D. D., & Dong, Y. (2023) · BMEMat · doi:10.1002/bmm2.12039 · Cited by 74
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant
Demaria, O., Gauthier, L., Vétizou, M., Blanchard-Alvarez, A., Vagne, C., Habif, G., Batista, L., Baron, W., Belaïd, N., Girard-Madoux, M. J. H., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100783 · Cited by 78
A highly efficient transgene knock-in technology in clinically relevant cell types
Allen, A. G., Khan, S., Margulies, C. M., Viswanathan, R., Lele, S. S., Blaha, L. C., Scott, S. N., Izzo, K. M., Gerew, A., Pattali, R. K., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01779-8 · Cited by 71
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial
Nieto, Y. L., Banerjee, P. P., Kaur, I., Başar, R., Li, Y., Daher, M., Rafei, H., Kerbauy, L. N., Kaplan, M., Marin, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03640-8 · Cited by 82
Self-citation
Expanding access to CAR T cell therapies through local manufacturing
Elsallab, M., & Maus, M. V. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01981-8 · Cited by 81
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial
Lei, W., Liu, H., Deng, W., Chen, W., Liang, Y., Gao, W., Yuan, X., Guo, S., Li, P., Wang, J., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00940-3 · Cited by 78
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
Ye, T., Li, F., Ma, G., & Wei, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113927 · Cited by 73
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 72
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 75
Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside
Zhang, B., Yang, M., Zhang, W., Liu, N., Wang, D., Jing, L., Xu, N., Yang, N., & Ren, T. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06438-7 · Cited by 73
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Li, Y.-R., Zhou, Y., Yu, J., Zhu, Y., Lee, D., Zhu, E., Li, Z., Kim, Y. J., Zhou, K., Fang, Y., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.005 · Cited by 73
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial
Huang, R., Wang, X., Yan, H., Tan, X., Ma, Y., Wang, M., Xiao, H., Liu, J., Gao, L., Gao, L., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00592-6 · Cited by 71
Self-citation
Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
Gudiol, C., Lewis, R. E., Strati, P., & Kontoyiannis, D. P. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30376-8 · Cited by 70
Arrested development: suppression of NK cell function in the tumor microenvironment
Riggan, L., Shah, S. N., & O’Sullivan, T. E. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1238 · Cited by 72
In Situ Programming of CAR T Cells
Parayath, N. N., & Stephan, M. T. (2021) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-070620-033348 · Cited by 73
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
Timofeeva, N., & Gandhi, V. V. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00467-7 · Cited by 70
Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors
Portillo, A. L., Hogg, R., Poznanski, S. M., Rojas, E. A. P., Cashell, N. J., Hammill, J. A., Chew, M. V., Shenouda, M. M., Ritchie, T. M., Cao, Q., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102619 · Cited by 69
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen, Q., Lu, L., & Ma, W. (2022) · Cancers · doi:10.3390/cancers14235983 · Cited by 73
Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
Arndt, C., Faßlrinner, F., Loureiro, L. R., Koristka, S., Feldmann, A., & Bachmann, M. P. (2020) · Cancers · doi:10.3390/cancers12051302 · Cited by 69
Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
Jamali, A., Hadjati, J., Madjd, Z., Mirzaei, H. R., Thalheimer, F. B., Agarwal, S., Bonig, H. B., Ullrich, E., & Hartmann, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02028 · Cited by 69
Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors
Wingert, S., Reusch, U., Knackmuss, S. H. J., Kluge, M., Damrat, M., Pahl, J. H. W., Schniegler‐Mattox, U., Mueller, T., Fucek, I., Ellwanger, K., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1950264 · Cited by 69
iPSC-Derived Natural Killer Cells for Cancer Immunotherapy
Karagiannis, P., & Kim, S. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0078 · Cited by 69
Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
Vito, C. D., Calcaterra, F., Coianiz, N., Terzoli, S., Voza, A., Mikulak, J., Bella, S. D., & Mavilio, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888248 · Cited by 69
Enhanced natural killer cell anti-tumor activity with nanoparticles mediated ferroptosis and potential therapeutic application in prostate cancer
Kim, K.-S., Choi, B., Choi, H., Ko, M. J., Kim, D., & Kim, D. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01635-y · Cited by 69
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 71
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers
Lee, S. C., Shimasaki, N., Lim, J. S. J., Wong, A. L., Yadav, K., Yong, W. P., Tan, L. K., Koh, L. P., Poon, M. L. M., Tan, S. H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0768 · Cited by 68
Unleashing TNF cytotoxicity to enhance cancer immunotherapy
Freeman, A. J., Kearney, C. J., Silke, J., & Oliaro, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.003 · Cited by 69
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
Dufva, O., Gandolfi, S., Huuhtanen, J., Dashevsky, O., Duàn, H., Saeed, K., Klievink, J., Nygren, P. J., Bouhlal, J., Lahtela, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.008 · Cited by 77
Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
Atilla, P. A., McKenna, M. K., Tashiro, H., Srinivasan, M., Mo, F., Watanabe, N., Simons, B. W., Stevens, A. M., Redell, M. S., Heslop, H. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001229 · Cited by 68
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Griggio, V., Perutelli, F., Salvetti, C., Boccellato, E., Boccadoro, M., Vitale, C., & Coscia, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594556 · Cited by 71
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia
Pastorczak, A. K., Domka, K., Fidyt, K., Poprzeczko, M., & Firczuk, M. (2021) · Cancers · doi:10.3390/cancers13071536 · Cited by 71
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Lei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K. H., & Qian, W. (2021) · Cancers · doi:10.3390/cancers13153912 · Cited by 70
Ex Vivo Generation of CAR Macrophages from Hematopoietic Stem and Progenitor Cells for Use in Cancer Therapy
Paasch, D., Meyer, J., Σταμοπούλου, Α., Lenz, D., Kuehle, J., Kloos, D., Buchegger, T., Holzinger, A., Falk, C. S., Kloth, C., et al. (2022) · Cells · doi:10.3390/cells11060994 · Cited by 73
Disruption of the NKG2A:HLA-E Immune Checkpoint Axis to Enhance NK Cell Activation against Cancer
Fisher, J. G., Doyle, A. D. P., Graham, L., Khakoo, S. I., & Blunt, M. D. (2022) · Vaccines · doi:10.3390/vaccines10121993 · Cited by 71
Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration
Alexander, M. D., Culos, K. A. A., Roddy, J. V. F., Shaw, J. R., Bachmeier, C. A., Shigle, T. L., & Mahmoudjafari, Z. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.014 · Cited by 71

Authors: Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Nunez Cortes, A., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Departments of Stem Cell Transplantation and Cellular Therapy (E.L., D.M., P.B., R.B., L.N.K., B.O., M. Kaplan, V.N., I.K., A.N.C., M.D., C.H., P.K., R.M., Y.N., R.C., E.J.S., K.R.), Nuclear Medicine (H.A.M.), Leukemia (P. Thompson, W.W., M. Keating), Biostatistics (P. Thall), Laboratory Medicine (K.C.), Hematopathology (E.N.C.), and Lymphoma and Myeloma (S.N., M.W.), University of Texas M.D. Anderson Cancer Center, Houston.
ORCID: Liu, Enli
Banerjee, Pinaki
Macapinlac, Homer A.
Thompson, Philip
Thall, Peter
Kaplan, Mecit
Cao, Kai
Daher, May
Hosing, Chitra
Cohen, Evan N.
Kebriaei, Partow
Mehta, Rohtesh
Neelapu, Sattva
Nieto, Yago
Wang, Michael
Wierda, William
Keating, Michael
Champlin, Richard
Shpall, Elizabeth J.
Rezvani, Katayoun
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2020-02-06
Volume: 382
Issue: 6
Pages: 545-553
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1910607
PMC: PMC7101242
OpenAlex: W3004611567
Cited by: 2,217
References: 37
Citations by year: 2026: 282 · 2025: 337 · 2024: 332 · 2023: 323 · 2022: 353 · 2021: 379 · 2020: 205
FWCI: 113.83
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: M.D. Anderson Cancer Center CLL and lymphoma Moonshot Grants
National Institutes of Health (1 R01 CA211044-01, 5P01CA148600-03, CA016672, P50CA100632-16)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CAR-NK cells, chimeric antigen receptor, natural killer cells, anti-CD19, relapsed or refractory B-cell lymphoma, chronic lymphocytic leukemia, Richter transformation, lymphodepleting chemotherapy, cytokine release syndrome, neurotoxicity, graft-versus-host disease, interleukin-6, CAR T-cell toxicity
MeSH terms: Receptors, Chimeric Antigen, Aged, Female, Fetal Blood, Genetic Vectors, Humans, Killer Cells, Natural, Lymphoma, Non-Hodgkin, Male, Middle Aged, Remission Induction, Retroviridae, Leukemia, Lymphocytic, Chronic, B-Cell, Antigens, CD19, Transplantation Conditioning, Allografts, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks